Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide.
Eur Urol
; 86(3): 268-271, 2024 Sep.
Article
in En
| MEDLINE
| ID: mdl-38772788
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Phenylthiohydantoin
/
Prostatic Neoplasms
/
Benzamides
/
Bone Neoplasms
/
Diffusion Magnetic Resonance Imaging
/
Nitriles
Limits:
Aged
/
Humans
/
Male
Language:
En
Journal:
Eur Urol
/
Eur. urol
/
European urology (Online)
Year:
2024
Document type:
Article
Country of publication:
Suiza